SEC Form 4	
------------	--

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address Salvadori Dan	<u>A</u>	2. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES</u> [ ABT ]							ationship of Reportin k all applicable) Director Officer (give title	Owner (specify					
(Last) 100 ABBOTT PA	(First) ARK ROAD	(Middle)	02	3. Date of Earliest Transaction (Month/Day/Year) 02/19/2021							below) EXECUTIVE V		ENT		
(Street) ABBOTT PARK	IL	60064	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi Line) X	,				
(City)	(State)	(Zip)									Form filed by More than One Reporting Person				
	Та	able I - Nor	n-Derivativ	ve Securities A	cquir	red, I	Disp	osed of, o	r Bene	ficially	Owned				
Date			2. Transaction Date (Month/Day/Y	Execution Da	te, Tr Co	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of ( 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			C	ode	v	Amount	t (A) or P		Transaction(s) (Instr. 3 and 4)	(1130.4)					
Common shares w	vithout par value		02/19/202	21		A		19,257(1)	Α	\$ <mark>0</mark>	121,690	D			

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(e.g., pulo, cullo, warranto, opriorio, convoluble occurrico)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option (right to buy) <sup>(2)</sup>	\$124.04	02/19/2021		Α		98,708		02/19/2022	02/18/2031	Common Shares	98,708	\$0	98,708	D	

## Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,902 on February 19, 2022, 32,903 on February 19, 2023, and 32,903 on February 19, 2024.

/s/ Daniel Gesua Sive Salvadori

by Jessica H. Paik, Attorney-in- 02/23/2021 Fact

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.